Programmed Innovation in Team Sport Using Needs Driven Innovation

AbstractInnovation is nothing new to sport, but represents everything that is ‘new’ and adopted to facilitate a competitive advantage. In the sport context, innovations that are solutions to a pre-identified problem or need are critical to developing sport and for maximising the experiences and performances of individuals and organisations. Advances in sport technology are part of the growing global sports and recreation industry, and at the individual level, technology innovation is changing the way that we practice and connect with sport. In this paper, we apply a model for programmed innovation in sport to an elite sport setting with a particular focus on team sports. Using a qualitative methodology we explore the perceptions of key stakeholders (such as sport managers, coaches, athletes, and science and engineering researchers) to investigate needs for technology innovation. The results demonstrate areas of key opportunity for technology innovation in the research and commercialisation context

Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy.

BACKGROUND: Recent literature has distinguished the negative symptoms associated with a diminished capacity to experience (apathy, anhedonia) from symptoms associated with a limited capacity for expression (emotional blunting, alogia). The apathy-anhedonia syndrome tends to be associated with a poorer prognosis than the symptoms related to diminished expression. The efficacy of drug-based treatments and psychological interventions for these symptoms in schizophrenia remains limited. There is a clear clinical need for new treatments. METHODS: This pilot study tested the feasibility of a program to reduce anhedonia and apathy in schizophrenia and assessed its impact on 37 participants meeting the ICD-10 criteria for schizophrenia or schizoaffective disorders. Participants were pre- and post-tested using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia (CDSS). They took part in eight sessions of the Positive Emotions Program for Schizophrenia (PEPS)--an intervention that teaches participants skills to help overcome defeatist thinking and to increase the anticipation and maintenance of positive emotions. RESULTS: Thirty-one participants completed the program; those who dropped out did not differ from completers. Participation in the program was accompanied by statistically significant reductions in the total scores for Avolition-Apathy and Anhedonia-Asociality on the SANS, with moderate effect sizes. Furthermore, there was a statistically significant reduction of depression on the CDSS, with a large effect size. Emotional blunting and alogia remain stable during the intervention. DISCUSSION: Findings indicate that PEPS is both a feasible intervention and is associated with an apparently specific reduction of anhedonia and apathy. However, these findings are limited by the absence of control group and the fact that the rater was not blind to the treatment objectives. CONCLUSIONS: PEPS is a promising intervention to improve anhedonia and apathy which need to be tested further in a controlled study. TRIAL REGISTRATION NUMBER: ISRCTN registry ISRCTN74048461, registered 18 may 2015

Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain

Background/Aim: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic side-effects, such as obesity and diabetes. This study examined the effects of low to high doses of olanzapine on appetite/ metabolic regulatory signals in the hypothalamus and brainstem to elucidate the mechanisms underlying olanzapineinduced obesity. Methodology/Results: Levels of pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and glutamic acid decarboxylase (GAD65, enzyme for GABA synthesis) mRNA expression, and cannabinoid CB1 receptor (CB1R) binding density (using [ 3 H]SR-141716A) were examined in the arcuate nucleus (Arc) and dorsal vagal complex (DVC) of female Sprague Dawley rats following 0.25, 0.5, 1.0 or 2.0 mg/kg olanzapine or vehicle (36/day, 14-days). Consistent with its weight gain liability, olanzapine significantly decreased anorexigenic POMC and increased orexigenic NPY mRNA expression in a dose-sensitive manner in the Arc. GAD65 mRNA expression increased and CB1R binding density decreased in the Arc and DVC. Alterations to neurotransmission signals in the brain significantly correlated with body weight and adiposity. The minimum dosage threshold required to induce weight gain in the rat was 0.5 mg/kg olanzapine. Conclusions: Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY. This study also supports a role for the CB1R and GABA in the mechanisms underlying weight gain side-effects, possibly b

IPCC, 2023: Climate Change 2023: Synthesis Report, Summary for Policymakers. Contribution of Working Groups I, II and III to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change [Core Writing Team, H. Lee and J. Romero (eds.)]. IPCC, Geneva, Switzerland.

This Synthesis Report (SYR) of the IPCC Sixth Assessment Report (AR6) summarises the state of knowledge of climate change, its widespread impacts and risks, and climate change mitigation and adaptation. It integrates the main findings of the Sixth Assessment Report (AR6) based on contributions from the three Working Groups1 , and the three Special Reports. The summary for Policymakers (SPM) is structured in three parts: SPM.A Current Status and Trends, SPM.B Future Climate Change, Risks, and Long-Term Responses, and SPM.C Responses in the Near Term.This report recognizes the interdependence of climate, ecosystems and biodiversity, and human societies; the value of diverse forms of knowledge; and the close linkages between climate change adaptation, mitigation, ecosystem health, human well-being and sustainable development, and reflects the increasing diversity of actors involved in climate action. Based on scientific understanding, key findings can be formulated as statements of fact or associated with an assessed level of confidence using the IPCC calibrated language

Particle size distribution of nitrated and oxygenated polycyclic aromatic hydrocarbons (NPAHs and OPAHs) on traffic and suburban sites of a European megacity: Paris (France)

The size distribution of particulate nitrated and oxygenated polycyclic aromatic hydrocarbons (NPAHs and OPAHs) was determined during two field campaigns at a traffic site in summer 2010 and at a suburban site during the MEGAPOLI (Megacities: Emissions, urban, regional and Global Atmospheric POLlution and climate effects, and Integrated tools for assessment and mitigation) experiment in summer 2009. Both, OPAHs and NPAHs were strongly associated (>85%) to fine particles (<i>D</i><sub>p</sub>< 2.5 μm) increasing the interest of their study on a sanitary point of view. Results showed really different NPAH and OPAH particle size distributions between both sites. At traffic site, clearly bimodal (notably for NPAHs) particle size distributions (<i>D</i><sub>p</sub> = 0.14 and 1.4 μm) were observed, while the particle size distributions were more scattered at the suburban site, especially for OPAHs. Bimodal particle size distribution observed at traffic site for the NPAH could be assigned to the vehicle emissions and the particle resuspension. Broadest distribution observed at the suburban site could be attributed to the mass transfer of compounds by volatilization/sorption processes during the transport of particles in the atmosphere. Results also showed that the combination of the study of particle size distributions applied to marker compounds (primary: 1-nitropyrene; secondary: 2-nitrofluoranthene) and to NPAH or OPAH chemical profiles bring some indications on their primary and/or secondary origin. Indeed, 1,4-anthraquinone seemed only primary emitted by vehicles while 7-nitrobenz[a]anthracene, benz[a]antracen7,12-dione and benzo[b]fluorenone seemed secondarily formed in the atmosphere